Athena Athena

X
[{"orgOrder":0,"company":"Celmatix","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Partner Celmatix Achieves Milestone For PCOS Drug Programme","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Celmatix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Novel PCOS drug target, is largely unknown, genomic studies suggest a strong genetic connection from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification.

            Lead Product(s): Undisclosed

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Evotec

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY